Categories: Entertainment

HUAWEI XMAGE Awards 2025 Open with Aim to Make Powerful Imaging Accessible to All

SHANGHAI, June 11, 2025 /PRNewswire/ — The HUAWEI XMAGE Awards 2025 officially kicked off during the HUAWEI Pura 80 launch event. This annual competition is a global showcase for Huawei mobile photography, and provides creators with a platform to share their work and convey the power of images to a broader audience. The competition has been held every year since 2017, and has attracted nearly five million total submissions from users in 170 countries and regions, making it one of the largest and most influential mobile photography competitions in the world.

- Advertisement -

Huawei’s XMAGE has long broken barriers in the world of mobile photography, by introducing groundbreaking telephoto, macro, night, snapshot, portrait, color, and videography capabilities that run the gamut. The recently unveiled HUAWEI Pura 80 smartphone series is chock full of trailblazing XMAGE innovations as well.

- Advertisement -

In light of this groundbreaking new product line, this year’s XMAGE Awards will include the following categories: So Far So Close, Good Night, and Colour & Shade, in addition to familiar favorites Faces, A Heartwarming World, Experimental Lab, Storyboard, and Action. The awards process will also change, with 1,000 outstanding works to be shortlisted by the judging panel, among which an “XMAGE 100” will be selected for special recognition, along with three Photographers of the Year.

- Advertisement -

This year’s panel consists of nine distinguished judges spanning a diverse range of professional backgrounds. They are: Liu Heung Shing, Pulitzer-Prize-winning photojournalist; Chen Xiaobo, Leading editor at Xinhua News Agency and imaging researcher; Wang Chuan, Professor and Doctoral Supervisor at Central Academy of Fine Arts and artist; Documentary photographer Chen Jie; Visual sociologist Nichole Fernandez; Florence Bourgeois, Director of Paris Photo; Shoair Mavlian, Director of The Photographers’ Gallery; Curator of visual arts Fannie Escoulen; and Li Changzhu, Chief Strategy Officer of the Huawei Health Team.

- Advertisement -

Registration for the XMAGE Awards 2025 is now open on the official competition website, My HUAWEI, HUAWEI Community, and Instagram. The submission deadline is September 15, 2025, 12 am Beijing time (GMT +8). We look forward to seeing all of this year’s amazing works, and celebrating another incredible year in mobile photography.

- Advertisement -

Official website: https://consumer.huawei.com/en/campaign/xmage

- Advertisement -

Photo – https://mma.prnewswire.com/media/2708415/thumbnail_image001.jpg 
Photo – https://mma.prnewswire.com/media/2708520/2e62c116f5fd0a34b2d2612d3ddd92e.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/huawei-xmage-awards-2025-open-with-aim-to-make-powerful-imaging-accessible-to-all-302478991.html

- Advertisement -
PRNW Agency

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

8 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

8 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

8 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

8 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

8 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

8 hours ago